Characteristics and outcomes in patients with lenalidomide-refractory multiple myeloma treated with 1-3 prior lines of therapy: Analysis of individual patient-level data from daratumumab clinical trials

The introduction of proteasome inhibitors (PIs) and lenalidomide as treatment for newly diagnosed multiple myeloma (MM) has led to an increased population of lenalidomide-refractory patients. Limited data are available characterizing current treatments and outcomes in this difficult-to-treat populat...

Full description

Saved in:
Bibliographic Details
Published in:European journal of cancer (1990) 2024-11, Vol.215, p.115157, Article 115157
Main Authors: Yong, Kwee, Einsele, Hermann, Schecter, Jordan M., Roccia, Tito, Deraedt, William, Lendvai, Nikoletta, Slaughter, Ana, Lonardi, Carolina, Connors, Kaitlyn, Qi, Keqin, Londhe, Anil, Carson, Robin, Kharat, Akshay, Cost, Patricia, Valluri, Satish, Mendes, João, Pacaud, Lida, Patel, Nitin, Florendo, Erika, Dhakal, Binod
Format: Article
Language:English
Subjects:
Daratumumab
Lenalidomide-refractory multiple myeloma
Lines of therapy
Outcomes
Real-world evidence
Standard of care
Treatment patterns
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The introduction of proteasome inhibitors (PIs) and lenalidomide as treatment for newly diagnosed multiple myeloma (MM) has led to an increased population of lenalidomide-refractory patients. Limited data are available characterizing current treatments and outcomes in this difficult-to-treat population. Individual patient-level data were analyzed from the treatment arms of multiple daratumumab studies, including APOLLO, CASTOR, CANDOR, EQUULEUS, ALCYONE, MAIA, GRIFFIN, POLLUX, and CASSIOPEIA. Included patients were PI exposed and lenalidomide refractory, received 1–3 prior lines of therapy (LOT), and had an Eastern Cooperative Oncology Group performance status
ISSN:0959-8049
1879-0852
1879-0852
DOI:10.1016/j.ejca.2024.115157